Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581917 · ClinicalTrials.gov registry record
Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia
A clinical trial of Recurrent Adult Acute Myeloid Leukemia and Untreated Adult Acute Myeloid Leukemia, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 14
- Enrollment target
- 1
- Study location
NCT02581917: Completed study of Recurrent Adult Acute Myeloid Leukemia and Untreated Adult Acute Myeloid Leukemia, sponsored by Wake Forest University Health Sciences.
NCT02581917 is a study of Recurrent Adult Acute Myeloid Leukemia and Untreated Adult Acute Myeloid Leukemia that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 14 participants, below the 54-participant average among 19 other Recurrent Adult Acute Myeloid Leukemia trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02581917, a study of Recurrent Adult Acute Myeloid Leukemia and Untreated Adult Acute Myeloid Leukemia, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This research trial studies metabolic changes in blood samples from patients with acute myeloid leukemia. Studying samples of blood from patients with acute myeloid leukemia in the laboratory may help doctors learn more about cancer and the development of drug resistance.
Primary Outcome
Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Cytology Specimen Collection Procedure
Study Locations (1)
North Carolina
- Comprehensive Cancer Center of Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-04-21 |
| Est. Completion | 2022-04-30 |
What the finished NCT02581917 record still lists
NCT02581917 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 54-participant average among 19 other Recurrent Adult Acute Myeloid Leukemia trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Recurrent Adult Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02581917 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02581917 about?
NCT02581917 is a clinical study titled "Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia". This research trial studies metabolic changes in blood samples from patients with acute myeloid leukemia. Studying samples of blood from patients with acute myeloid leukemia in the laboratory may help doctors learn more about cancer and the development of drug resistance.
What is the current status of trial NCT02581917?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2017-04-21. Estimated completion is 2022-04-30.
What conditions does trial NCT02581917 study?
This clinical trial studies the following conditions: Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia.
What interventions are being tested in trial NCT02581917?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cytology Specimen Collection Procedure (OTHER).
Who is sponsoring clinical trial NCT02581917?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02581917 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adult Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02581917's enrollment target sits among peer trials
14 17th of 19 higher than 3 of 19 other Recurrent Adult Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Adult Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RECRUITING · Phase 1
-
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
RECRUITING · Phase 1
-
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy